Hematologic Malignancy Clinical Trials & Research at Providence Medical Group
Providence Medical Group is currently enrolling patients for the following
hematologic malignancy clinical trials:
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR)
Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic
Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)
Treatment agent: Pirtobrutinib (LOXO), venetoclax, Rituxamab
PI: Jarrod Holmes, MD
Study Coordinator: Teresa Lund //Teresa.Lund@stjoe.org// (707) 521-3803
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04965493?term=NCT04965493&draw=2&rank=1
Sponsor: Loxo